BONUS CAP-ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000VM4A0Q7

Market Closed - Deutsche Boerse AG 14:02:37 2024-06-14 EDT
286.7 EUR +0.77% Intraday chart for BONUS CAP-ZERTIFIKAT - ROCHE GS
Current month+4.60%
1 month+6.15%
Date Price Change
24-06-14 286.7 +0.77%
24-06-13 284.5 +0.87%
24-06-12 282 -0.04%
24-06-11 282.2 +0.51%
24-06-10 280.7 -0.01%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 02:02 pm

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM4A0Q
ISINDE000VM4A0Q7
Date issued 2023-10-23
Strike 280 CHF
Maturity 2024-12-20 (188 Days)
Parity 1 : 1
Emission price 269.8
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 287.1
Lowest since issue 260.7
Spread 3.38
Spread %1.17%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus